Price (delayed)
$3.39
Market cap
$71.22M
P/E Ratio
3.46
Dividend/share
N/A
EPS
$0.98
Enterprise value
$31.24M
Ocuphire is a publicly traded, clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire's pipeline currently includes two small- molecule product
There are no recent dividends present for OCUP.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.